Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab-Reference-Cited by-同舟云学术

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Published:2017-05-02 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Marisi Giorgia,Scarpi Emanuela,Passardi Alessandro,Nanni Oriana,Ragazzini Angela,Valgiusti Martina,Casadei Gardini Andrea,Neri Luca Maria,Frassineti Giovanni Luca,Amadori Dino,Ulivi Paola

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-01420-0.pdf

Reference30 articles.

1. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342, doi: 10.1056/NEJMoa032691 (2004).

2. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019, doi: 10.1200/JCO.2007.14.9930 (2008).

3. Hochster, H. S. et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol. 26, 3523–3529, doi: 10.1200/JCO.2007.15.4138 (2008).

4. Ciombor, K. K. & Berlin, J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers. Med. 7, 137–144, doi: 10.2147/PGPM.S47582 (2014).

5. Hegde, P. S. et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin. Cancer Res. 19, 929–937, doi: 10.1158/1078-0432.CCR-12-2535 (2013).

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging;Cancers;2024-03-30

2. Network Pharmacology and Bioinformatics Study of Geniposide Regulating Oxidative Stress in Colorectal Cancer;International Journal of Molecular Sciences;2023-10-16

3. Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial;Frontiers in Oncology;2023-05-03

4. Elevated Preoperative Serum Vascular Endothelial Growth Factor Does Not Predict Poor Outcomes in Curatively Resected Non-metastatic Colorectal Cancer Treated Without Neoadjuvant Therapy;Anticancer Research;2023-04-25

5. Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab;Cancers;2022-06-21